Pharmacology Final

39 Questions

Settings
Please wait...
Pharmacology Quizzes & Trivia

Polymorphisms (taken from Daoud's lectures) and how they affect diseases, drugs, and populations


Questions and Answers
  • 1. 
    What is the functional effect of HLA-B*5701?
    • A. 

      Causes increased plasma levels of omeprazole (increased H. pylori cure rates)

    • B. 

      Transports large molecules (like statins) along microtubules (decreases CHD risk)

    • C. 

      Causes increased statin plasma levels (increased toxicity)

    • D. 

      High risk of abacavir-induced hypersensitivity reaction

  • 2. 
    What polymorphism will cause increased H. pylori cure rates with patients on omeprazole
    • A. 

      CYP2C19*3

    • B. 

      KIF6719Trp

    • C. 

      CYP2C9

    • D. 

      UGT1A1 *1/*28

  • 3. 
    Highest prevalence for CYP2D6*17
    • A. 

      Asians

    • B. 

      African Americans

    • C. 

      Caucasians

  • 4. 
    KIF6 719 Trp/Arg SNP increases the risk of CHD (cannot transport statin along microtubule)
    • A. 

      True

    • B. 

      False

  • 5. 
    Has been associated with inter-individual variability in warfarin dose requirements
    • A. 

      CYP2C9

    • B. 

      VKORCI

    • C. 

      CYP4F2

    • D. 

      CYP2D6

  • 6. 
    Pre-menopausal women can switch to aromatase inhibitors (Anastrazole, Letrozole, Exestrone) if they have CYP2D6*4/*4
    • A. 

      True

    • B. 

      False

  • 7. 
    TPMT *3A, *3C, *2 Functional effect
    • A. 

      Cause deficiency of TPMT- leading to decreased clearance of inactive methylated metabolites and increased toxicity

    • B. 

      Causes a buildup of TMPT leading to toxicity

    • C. 

      Causes build up for TMP leading to decreased effect

  • 8. 
    Patient with HIV should not use abacavir if they are positive for  HLA-B*5701
    • A. 

      True

    • B. 

      False

  • 9. 
    CYP2C9*2 causes there to be no enzyme activity (increased warfarin effect)
    • A. 

      True

    • B. 

      False

  • 10. 
    Highest prevalence for KIF6719Trp/Arg
    • A. 

      Caucasian

    • B. 

      Asian

    • C. 

      African American

  • 11. 
    Increases statin concentrations thus increases the risk for myopathy
    • A. 

      CYP2C9*3

    • B. 

      SLCO1B1*5

    • C. 

      UGT1A1 *28

    • D. 

      CKORC1 polymorphism

  • 12. 
    SLCO1B1*5 Population Prevalence (check all that apply)
    • A. 

      Caucasian 16%

    • B. 

      Asian 10-16%

    • C. 

      African American 1-2%

    • D. 

      African American 5%

  • 13. 
    CYP2C9*3 has 5% enzyme activity (meaning must reduce warfarin dosing)
    • A. 

      True

    • B. 

      False

  • 14. 
    Highest prevalence of UGT1A1 *1/*1 (wildtype)
    • A. 

      Caucasian

    • B. 

      Asian

    • C. 

      African American

  • 15. 
    Highest prevalence of UGT1A1 *1/*28
    • A. 

      Caucasians

    • B. 

      Asians

    • C. 

      African Americans

  • 16. 
    Highest prevalence of UGT1A1 *28/*28
    • A. 

      Caucasian

    • B. 

      Asian

    • C. 

      African American

  • 17. 
    SLCO1B1 encodes for OAT1B1
    • A. 

      True

    • B. 

      False

  • 18. 
    Transports statins (except fluvastatin) to hepatocytes
    • A. 

      OAT1B1

    • B. 

      SLCO1B

    • C. 

      UGT1A1

  • 19. 
    UGT1A1*28 toxicities (for irinotecan)- check all that apply
    • A. 

      Hepatotoxicity

    • B. 

      Some diarrhea

    • C. 

      Severe neutropenia

    • D. 

      Head ache

  • 20. 
    Someone with a KRAS mutation has a low likelihood of response to anti-EGFR therapy (monoclonal antibody)
    • A. 

      True

    • B. 

      False

  • 21. 
    SNP (521T>C) nucleotide change in SLCOIBI*5 results in an amino acid change 174 Val --> Ala (decreases transport activity)
    • A. 

      True

    • B. 

      False

  • 22. 
    KIF6719Trp: wild type; KIF6 encodes kinesin-like protein 6 to transport large molecules along microtubules
    • A. 

      True

    • B. 

      False

  • 23. 
    Anti-EGFR therapy drugs are Cetuximab and Ponitumumab
    • A. 

      True

    • B. 

      False

  • 24. 
    Gold standard endocrine therapy for patients with estrogen receptor positive or progesterone receptor positive breast cancer
    • A. 

      Tamoxifen

    • B. 

      Cetuximab

    • C. 

      Estradiol

    • D. 

      None of the above

  • 25. 
    Tamoxifen is the active metabolite of endoxifen
    • A. 

      True

    • B. 

      False

  • 26. 
    Highest population prevalence for CYP2D6*4 (no enzyme activity)
    • A. 

      Caucasian

    • B. 

      Asian

    • C. 

      African American

  • 27. 
    CYP2D6 converts Tamoxifen to Endoxifen
    • A. 

      True

    • B. 

      False

  • 28. 
    Highest population prevalence for those taking abacavir and have HLA-B*5701
    • A. 

      Caucasian

    • B. 

      Asian

    • C. 

      African American

  • 29. 
    VKORCI-1639 A/A has a population prevalence of 99% for Asians
    • A. 

      True

    • B. 

      False

  • 30. 
    CYP2D6 alleles associated with decreased enzyme activity (less active metabolite): check all that apply
    • A. 

      *17x2

    • B. 

      *10

    • C. 

      *17

    • D. 

      *41

  • 31. 
    CYP2D6 alleles associated with no (null) enzyme activity: check all that apply
    • A. 

      *3

    • B. 

      *4

    • C. 

      *5

    • D. 

      *6

  • 32. 
    CYP2D6*17x2 and *41x2 are alleles associated with INCREASED enzyme activity (more active metabolite)
    • A. 

      True

    • B. 

      False

  • 33. 
    Highest prevalence of CYP2C19*3
    • A. 

      Caucasian

    • B. 

      Asian

    • C. 

      African American

  • 34. 
    CYP2C9 and CKORC1 polymorphisms impact warfarin EFFICACY and TOXICITY
    • A. 

      True

    • B. 

      False

  • 35. 
    Highest population prevalence for CYP2D6*10 (decreased enzyme activity)
    • A. 

      Caucasian

    • B. 

      Asian

    • C. 

      African American

  • 36. 
    TPMT*3A is the most common allele in Caucasians
    • A. 

      True

    • B. 

      False

  • 37. 
    TPMT*3C is the most common allele in Caucasians
    • A. 

      True

    • B. 

      False

  • 38. 
    CYP2C9*2 has the highest population prevalence in Caucasians
    • A. 

      True

    • B. 

      False

  • 39. 
    CYP2C9*5, *6, *8, *11 predominantly occur in individuals of African descent
    • A. 

      True

    • B. 

      False